Spatial transcriptomics in diabetic macular ischaemia
MDFA is Australia’s largest source of research funding in the field of macular disease outside of government
Composition and functionality of high-density lipoprotein in age-related macular degeneration and a high-risk disease phenotype
Redefining macular disease diagnosis to improve access to emerging therapies
Investigating mitochondrial dysfunction in macular degeneration – towards new treatments and biomarkers
Evaluating the potential of hyperspectral imaging for detecting and monitoring geographic atrophy Accurate monitoring of
Vabysmo is a new treatment for age-related macular degeneration and diabetic macular oedema and is now available on the Pharmaceutical Benefits Scheme (PBS) in Australia
MDFA 2022 research update
MDFA is committing to macular disease research